The following abstracts and articles were generated by Dr

Fact Sheet		Preparation & Outcome Enhancement
Outcomes and Case Studies		Upcoming Lectures
Frequently Asked Questions		Contacting Us
Policies of AMRI of NW Ohio		MME Home Page
Messages from Dr. Roberts		Heartfixer Welcome Page
		Reverse Heart Disease Now Home Page

No Longer Available

Abstracts and Publications

The following abstracts and articles were generated by Dr. Bonlie and the original four US MME sites:

Abstract One - Clinical observations on Magnetic Molecular Energizer in Multiple Sclerosis patients

Abstract Two - Five ton standing magnet: Its use in treatment of Cerebral Palsy -- A preliminary report

Abstract Three - Clinical observations on MME in Alzheimer's and Parkinson's patients and their possible association with heavy metals

Study One - Clinical Observations on Magnetic Molecular Energizer in Parkinson's Disease - A Pilot Study

Abstract One - CLINICAL OBSERVATIONS ON MAGNETIC MOLECULAR ENERGIZER ON MULTIPLE SCLEROSIS PATIENTS

Contributing Authors:
1. T.W. Nichols AMRI-PA, Hanover, PA, USA
2. L.A. Pearce AMRI-NC, Mocksville, NC, USA
3. D.L. Stokesbary AMRI-CA, Laguana Nigel, CA, USA
4. D.R. Bonlie AMRI-AB, Calgary, AB, Canada

Magnetic Molecular Energizer (MME) is an IRB approved, experimental treatment which has been performed on 12 patients with multiple sclerosis, with 10 having marked improvement, (range 86-1190 hours). The two patients who did not improve had either only 26 hours of treatment time or were in an acute relapse. MME consists of two DC electromagnets (0.5 tesla) with the patient lying in the focal point between the two magnets. When the MME device treats the patient, there is a temporary increase in the magnetic force on the atoms of the body in the focal point. The force results in a higher velocity of some of the orbiting electrons causing precession or wobble. Combined with the higher velocity this leads to enhanced electron transfer, which is the basis of all chemical reactions in the body. We also hypothesize that prolonged improvement seen in these patients and other neurodegenerative diseases such as Alzheimer's and Parkinson's implicates up regulation of neural stem cells. The effect of 0.2 tesla static magnetic field on human neurons in cell culture by Pacini demonstrated dramatic changes of morphology, with formation of vortexes of cells and exposed branched neurites featuring synaptic buttons after 15 min.¹ A double blind, sham controlled, cross over trial in human patients with Parkinson's is beginning shortly in collaboration with several major university medical centers Neurosci Lett 1999 4;267:185-8.

¹ Pacini S, Vannelli GB, Barni T, Ruggiero M, et al. Effect of 0.2 T magnetic field on human neurons: remodeling and inhibition of signal transduction without genome instability.

Abstract Two - FIVE-TON STANDING MAGNET: ITS USE IN TREATMENT OF CEREBRAL PALSY--A PRELIMINARY REPORT.

Contributing Authors:
1. L.A. Pearce AMRI-NC, Mocksville, NC, USA
2. T.W. Nichols AMRI-PA, Hanover, PA, USA
3. D.L. Stokesbary AMRI-CA, Laguana Nigel, CA, USA
4. D.R. Bonlie AMRI-AB, Calgary, AB, Canada
5. D. Goodman Newport Neuroscience Center, San Marcos, CA, USA

Since treatment for many of the severely disabling neurologic disorders is symptomatic at best, therapies capable of regenerating tissues are needed. Preliminary clinical trials using a new magnetic device, the MME, show maintained symptom amelioration and disability reduction which suggests tissue regeneration. The device, similar to an open MRI scanner, generates a unidirectional 5000 gauss static magnetic field. The patient lies between two cones of the device. Changes in clinical status were scored according to an open label protocol after placement under the device for a specified period. Of an initial 114 patients receiving magnetic treatment 75 showed significant improvement. The most promising results were seen in cerebral palsy where 7 of 7 patients improved. A 40 year old patient, quadriplegic since birth, became ambulatory following 200 hours of treatment. In addition to gait improvement, the patient's scored neurologic evaluation showed significant changes in spasticity, motor performance, speech, and swallowing which were maintained for follow-up periods of over a year. Patients treated for Parkinson's disease, CNS injury, stroke, and MS also seemed to benefit. Among the explanations that might account for clinical improvement are that magnetic fields may have primary effects on circulation, oxygen uptake, and energy production. Another possibility is that magnetic fields activate stem cells resulting in enhanced tissue regeneration. Double blind studies are planned to further assess the therapeutic potential of the MME.

Abstract Three - CLINICAL OBSERVATIONS ON MAGNETIC MOLECULAR ENERGIZING ON ALZHEIMER'S AND PARKINSON'S PATIENTS AND THEIR POSSIBLE ASSOCIATION WITH HEAVY METALS

Molecular Energizing (MME) is an IRB approved, experimental treatment consisting of two strong, non-pulsating DC electromagnets (5000 gauss) with the patient lying in a focal point between the two magnets. When the patient is treated with the MME device there is a temporary increase in the magnetic force on the atoms of the body in the focal point. The force results in a higher velocity of some of the orbiting electrons causes precession or wobble of the atom. Combined with the higher velocity this leads to enhanced electron transfer, which is the basis of all chemical reactions in the body. Seventeen patients with Parkinson's (PD) disease have been treated with nine definitely improving in symptoms (91-308 hrs). Seven Alzheimer's (AD) patients have been treated, with four (100-259 hrs) improving in cognition, and memory. Heavy metals appeared to be liberated from patients during the first several days of MME and the protocol now requires the administration of DMSA (Chemet 500 mg) before each treatment session to lessen side affects. Both Alzheimer's and Parkinson's have genetic as well as environmental factors in response to heavy metals in particular. Iron, calcium, aluminum, and mercury have been implicated in AD and iron and mercury in PD. Heavy metals increase oxidative stress via the Fenton reaction and cadmium, lead and mercury have demonstrated uncoupling of mitochondrial oxidative phosphorylation. MME is hypothesized to liberate heavy metals from the brain, up regulate cytoprotective enzymes and increase tissue regeneration.

AMRI of NW Ohio provides MME treatment under the guidelines of an Investigational Review Board, consistent with FDA regulations.

Please note that MME treatment is considered to be experimental by the FDA. Although many patients have improved, no guarantee of success is implied.